Ostearthritis is one of the most common arthritis, affecting more than 30% of aged people world-widely. The disease is characterized by pain and stiffness of the affected joints and is the most common cause of disability in aged people. It commonly affects knee, hip, hand and spine joints. Diacerein is a drug developed specifically for the treatment of osteoarthritis. It has inhibitory effects on interleukin-1 (IL-1) and metalloproteases which are known to play key roles in the pathogenesis of osteoarthritis while exerting no effect on phospholipase A2, cyclooxygenase or lipoxygenase. It showed anti-inflammatory effects on animal models and reduced structural changes in several animal models. Therefore, we investigate the role of diacerein in patients with hand osteoarthritis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
86
Diacerein 50mg bid
placebo
Seoul National University Hospital
Seoul, South Korea
Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain score at 4 week point
Time frame: 12 weeks
AUSCAN stiffness score at 4 week point
Time frame: 12wks
AUSCAN pain score at 12 week point
Time frame: 12wk
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.